Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24500280 | 0.85 | CHRNA7 (0.44) | CHRNA7SMN1; SMN2KDM4EGAAMAPT | |
| SCHEMBL18653836 | 0.85 | CHRNA7 (0.38) | CHRNA7SMN1; SMN2ENPP2KDM4EGAA | |
| SCHEMBL22260437 | 0.83 | CHRNA7 (0.42) | CHRNA7SMN1; SMN2NR1H2NR1H3KDM4E | |
| SCHEMBL14299649 | 0.82 | CHRNA7 (0.60) | CHRNA7KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL12695033 | 0.82 | CHRNA7 (0.46) | CHRNA7SMN1; SMN2KDM4EGAAMAPT | |
| SCHEMBL20098094 | 0.82 | ALDH1A1 (0.36) | SMN1; SMN2PTGS2PTGS1MAPTALDH1A1 | |
| SCHEMBL8820079 | 0.79 | SMN1; SMN2 (0.47) | CHRNA7SMN1; SMN2KDM4EGAAMAPT | |
| SCHEMBL16172616 | 0.79 | ALDH1A1 (0.44) | CHRNA7SMN1; SMN2KDM4EGAAMAPT | |
| SCHEMBL1853273 | 0.79 | SYK (0.39) | CHRNA7SMN1; SMN2ENPP2KDM4EGAA | |
| SCHEMBL16172620 | 0.78 | CHRNA7 (0.43) | CHRNA7SMN1; SMN2NR1H2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024028243-A1 | PYRAZOLO PESTICIDAL COMPOUNDS | BASF SE (DE) | 2024-02-08 | — | — | WO | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | UNIVERSITY OF OULU (FI) | 2023-10-12 | — | — | US | disclosed |
| US-8716274-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20070249629-A1 | Viral Polymerase Inhibitors | BEAULIEU PIERRE | 2007-10-25 | — | — | US | disclosed |
| US-20070249629-A1 | Viral Polymerase Inhibitors | BEAULIEU PIERRE | 2007-10-25 | — | — | US | disclosed |
| US-7241801-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241801-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | CHRNA7 1248/4885SMN1; SMN2 423/4885PTGS2 3256/4885 |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | CBR3, GBA3, TECR | CHRNA7 4333/4885SMN1; SMN2 3972/4885PTGS2 782/4885 |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | MERTK, DAPK1, AXL | CHRNA7 4606/4885SMN1; SMN2 1632/4885PTGS2 4129/4885 |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | CHRNA7 4739/4885SMN1; SMN2 3470/4885PTGS2 3971/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | CHRNA7 4192/4885SMN1; SMN2 3277/4885PTGS2 2724/4885 |
| US-20070249629-A1 | Viral Polymerase Inhibitors | RPP30, POLR2A, POLR1E | CHRNA7 3891/4885SMN1; SMN2 2418/4885PTGS2 4230/4885 |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | MERTK, DAPK1, AXL | CHRNA7 4606/4885SMN1; SMN2 1632/4885PTGS2 4129/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CHRNA7 4842/4885SMN1; SMN2 3156/4885PTGS2 2744/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | CHRNA7 2590/4885SMN1; SMN2 1994/4885PTGS2 2208/4885 |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | CHRNA7 1356/4885SMN1; SMN2 3164/4885PTGS2 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.